Condition
Unresectable Cancer
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Terminated1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07423169Not ApplicableRecruiting
Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
NCT07339488Phase 2Active Not Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
NCT02274038Not ApplicableTerminated
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
Showing all 3 trials